Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Reumatología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Reclutando
ClinicalTrials.gov
Prospective Multi-country, Real-world, Multi-arm Study of Treatment PErsistence With RISankizumab in Psoriatic Arthritis (PERIS)
OBSERVATIONAL
Inicio: 31 de ene de 2025
ID: NCT06764693
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
INTERVENTIONAL
Inicio: 9 de may de 2017
ID: NCT03129100
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)
INTERVENTIONAL
Inicio: 12 de ene de 2015
ID: NCT02003144
Completado
ClinicalTrials.gov
Real World Effectiveness of Upadacitinib on Early and Sustained Pain Control in Axial Spondylarthritis (UPSTAND)
OBSERVATIONAL
Inicio: 30 de abr de 2021
ID: NCT04846244
Completado
Fase 2
ClinicalTrials.gov
Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety/Pharmacokinetics of BMS-986142 in Subjects With Moderate to Severe Rheumatoid Arthritis With an Inadequate Response to Methotrexate With or Without TNF Inhibitors
INTERVENTIONAL
Inicio: 16 de feb de 2016
ID: NCT02638948
Reclutando
Fase 2
ClinicalTrials.gov
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
INTERVENTIONAL
Inicio: 23 de abr de 2025
ID: NCT06928142
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
INTERVENTIONAL
Inicio: 1 de dic de 2012
ID: NCT01721057
Completado
ClinicalTrials.gov
Argentinian Registry of Patients With Rheumatic Diseases and COVID-19 Infection
OBSERVATIONAL
Inicio: 18 de ago de 2020
ID: NCT04568421
Completado
Fase 2
ClinicalTrials.gov
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
INTERVENTIONAL
Inicio: 31 de ago de 2017
ID: NCT03161483
Terminado
Fase 3
ClinicalTrials.gov
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety, Tolerability and Usability up to 5 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents
INTERVENTIONAL
Inicio: 1 de oct de 2012
ID: NCT01770379
Completado
Fase 2
ClinicalTrials.gov
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
INTERVENTIONAL
Inicio: 1 de jun de 2011
ID: NCT01373151
Completado
Fase 1
ClinicalTrials.gov
Phase Ib, Multicenter, Randomized, Open-Label, Parallel-Group Study to Characterize the Pharmacokinetics of a Single Dose of Abatacept 125 mg Administered Subcutaneously Using the BD Physioject™ Autoinjector or the UltraSafe Passive Needle Guard Prefilled Syringe
INTERVENTIONAL
Inicio: 1 de jul de 2013
ID: NCT01890473
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects With Moderately to Severely Active Rheumatoid Arthritis
INTERVENTIONAL
Inicio: 23 de feb de 2016
ID: NCT02706873
Desconocido
ClinicalTrials.gov
Measuring Synovial Fluid Components
INTERVENTIONAL
Inicio: 1 de abr de 2022
ID: NCT05416255
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
INTERVENTIONAL
Inicio: 17 de dic de 2015
ID: NCT02675426
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Phase II, Double-blind, Dose-Ranging, Parallel, Long-term Extension Study to Evaluate the Safety and Efficacy of Enpatoran in Participants With Subacute Cutaneous Lupus Erythematosus, Discoid Lupus Erythematosus and/or Systemic Lupus Erythematosus Having Completed the WILLOW (MS200569_0003) Study Treatment (WILLOW LTE)
INTERVENTIONAL
Inicio: 16 de sept de 2022
ID: NCT05540327
Terminado
Fase 3
ClinicalTrials.gov
A Two-year, Phase III Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 mg s.c. Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis
INTERVENTIONAL
Inicio: 7 de jul de 2020
ID: NCT04181762
Completado
Fase 2
ClinicalTrials.gov
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in SLE and in CLE (SCLE and/or DLE) Participants Receiving Standard of Care (WILLOW)
INTERVENTIONAL
Inicio: 31 de mar de 2022
ID: NCT05162586
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Placebo Controlled, Multicenter Clinical Study Investigating Efficacy of Rituximab in the Inhibition of Joint Structural Damage Assessed by Magnetic Resonance Imaging in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate
INTERVENTIONAL
Inicio: 1 de nov de 2007
ID: NCT00578305
Completado
Fase 2
ClinicalTrials.gov
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
INTERVENTIONAL
Inicio: 1 de dic de 2013
ID: NCT01972568
Anterior
1
...
4
5
6
...
434
Siguiente
Filtros